Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Scancell Holdings PLC to present at World Vaccine Congress

Dr Peter Brown, Scancell's clinical and scientific consultant on Immunotherapeutics, will give a presentation entitled: "SCIB1 ImmunoBody stimulates a potent T cell response that eradicates tumours and prevents recurrence".
Scancell Holdings PLC to present at World Vaccine Congress
In patients with resected (excised) disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell Holdings PLC's (LON:SCLP) Dr Peter Brown is to present an update on the company's SCIB1 ImmunoBody cancer vaccine at this year's World Vaccine Congress.

The presentation, entitled: "SCIB1 ImmunoBody stimulates a potent T cell response that eradicates tumours and prevents recurrence", will be presented on Wednesday 30 March 2016 at 11.40am EDT at the congress in Washington DC.

Dr Brown is Scancell's clinical and scientific consultant on Immunotherapeutics.

Scancell's first ImmunoBody, SCIB1, is currently being evaluated in a Phase 1/2 clinical trial in patients with Stage III/IV melanoma. The latest data suggests that SCIB1 may have the potential to significantly extend survival times in patients, especially in those with resected disease. 

Scancell is in the process of preparing a final clinical study report. A Phase 2 checkpoint inhibitor combination study of SCIB1 in melanoma is due to commence in 2017.

"We are delighted to be presenting an update on SCIB1 at the World Vaccine Congress, alongside some of the most distinguished companies in the immunotherapy field,” said Richard Goodfellow, joint chief executive officer of Scancell.

“Funds from the recently announced  placing and the pending open offer will be used to further progress our ImmunoBody and Moditope platforms, including helping to fund our expanded SCIB1 clinical trial programme, which will be led by a team of leading US specialists," he added.

John-H.jpg
Why Invest In Scancell Holdings Plc? Read More Here

Register here to be notified of future SCLP Company articles
View full SCLP profile

Scancell Holdings Plc Timeline

Related Articles

1-SG02055.jpg
March 22 2016
e-Therapeutics is now targeting partners to accelerate the development of its drug discovery engine and commercialise compounds.
immupharma-_kiss_pic_with_mum.png
March 01 2016
Lupuzor is not the only part of the Immupharma story and McCarthy plans also to raise the profile of the rest of the group's early stage pipeline in 2016.....
rsz_shutterstock_118277080.jpg
August 02 2016
Horizon Discovery is a machine, which keeps motoring, underlined by the life sciences group's positive update on 2015 trading.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.